clarithromycin has been researched along with vonoprazan in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (34.52) | 24.3611 |
| 2020's | 55 (65.48) | 2.80 |
| Authors | Studies |
|---|---|
| Horio, A; Kamiya, K; Nishio, E; Tokura, Y | 1 |
| Asaka, M; Funao, N; Murakami, K; Nishimura, A; Sakurai, Y; Shiino, M | 1 |
| Ishihara, S; Kawashima, K; Kinoshita, Y | 1 |
| Gotoda, T; Iwatsuka, K; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Hasegawa, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakurai, Y; Shiino, M | 1 |
| Fukui, K; Hayakawa, Y; Hirata, Y; Isomura, Y; Ito, Y; Koike, K; Matsuo, K; Mochizuki, S; Niikura, R; Okamoto, M; Omae, T; Seto, M; Shichijo, S; Sugimoto, T; Suzuki, H; Suzuki, N; Takano, N; Togo, G; Watabe, H; Yamada, A; Yamamoto, S | 1 |
| Fujita, M; Graham, DY; Haruma, K; Ishii, M; Kamada, T; Katsumata, R; Matsumoto, H; Murao, T; Nakato, R; Shiotani, A | 1 |
| Adachi, K; Ebi, M; Funaki, Y; Goji, S; Izawa, S; Kasugai, K; Noda, H; Noguchi, S; Ogasawara, N; Sasaki, M; Tamura, Y; Yamamoto, S; Yoshimine, T | 1 |
| Kajihara, Y; Mizuki, I; Shimoyama, T | 1 |
| Jenkins, H; Jenkins, R; Patat, A | 1 |
| Eguchi, T; Fujita, M; Fukuchi, T; Hashimura, H; Kanamori, A; Kano, C; Koizumi, A; Matsumoto, K; Momose, K; Okada, A; Shimoyama, K; Tsujimae, M; Yamashita, H | 1 |
| Kato, M; Mabe, K; Nakagawa, S; Ono, S; Sakamoto, N | 1 |
| Hasuda, K; Hattori, M; Ido, Y; Okuda, A; Sakurai, K; Suda, H; Takeichi, T | 1 |
| Fujisawa, T; Horiuchi, A; Imai, R; Kimura, T; Kiyosawa, K; Kubota, D; Maruyama, M; Matsuda, Y; Miyajima, M; Mori, H; Tanaka, N; Tokutake, K; Wada, S | 1 |
| Jung, YS; Kim, EH; Park, CH | 1 |
| Hu, Y; Lu, NH; Zhu, Y | 1 |
| Amano, H; Arima, I; Fukuchi, T; Ikeda, A; Inokuchi, Y; Ishii, Y; Iwase, S; Iwata, Y; Kanno, M; Kawana, I; Kokawa, A; Komatsu, K; Kondo, M; Kunishi, Y; Kuwashima, H; Maeda, S; Miwa, H; Morimoto, M; Naito, M; Oka, H; Okazaki, H; Saito, T; Sanga, K; Sasaki, T; Shibata, W; Sue, S; Takahashi, D; Tamura, T; Terada, M | 1 |
| Ando, K; Fujinaga, A; Fujiya, M; Goto, M; Ichiishi, E; Ito, T; Kashima, S; Kawamoto, T; Kohgo, Y; Moriichi, K; Nomura, Y; Okumura, T; Otake, T; Sato, K; Sato, T; Sugano, H; Tanabe, H; Ueno, N; Utsumi, T; Yanagawa, N | 1 |
| Gotoda, T; Ikehara, H; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Arima, I; Kaneko, H; Komatsu, K; Kondo, M; Kuwashima, H; Maeda, S; Naito, M; Nakao, S; Ogushi, M; Sasaki, T; Shibata, W; Sue, S; Tamura, T | 1 |
| Moss, SF; Pellicano, R; Saracco, GM; Zagari, RM; Zhang, S | 1 |
| Fukui, H; Horikawa, T; Li, M; Miwa, H; Oshima, T; Tomita, T; Tozawa, K; Watari, J | 1 |
| Ando, K; Fujiya, M; Ichiishi, E; Ishizuka, A; Kohgo, Y; Nomura, Y; Ohta, K; Okumura, T; Otake, T; Satoh, K; Tanabe, H; Yoshino, K | 1 |
| Hayashi, Y; Kobayashi, Y; Lefor, AK; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Endo, H; Fujimoto, K; Hara, M; Hidaka, H; Kawachi, K; Matsunaga, T; Nakano, R; Sakata, Y; Shimoda, R; Takara, Y; Tsuruoka, N | 1 |
| Fukuba, N; Ishitobi, H; Kinoshita, Y; Kobayashi, Y; Komazawa, Y; Kusunoki, M; Nagaoka, M; Shizuku, T; Takahashi, Y; Yuki, M | 1 |
| Kiyotoki, S; Nishikawa, J; Sakaida, I | 1 |
| Fukui, K; Hayashi, S; Higaki, Y; Inada, M; Matsubara, T; Mukai, K; Nakajima, S; Nakamatsu, D; Nishida, T; Okamoto, A; Osugi, N; Sugimoto, A; Takahashi, K; Tomita, R; Tsujii, Y; Yamamoto, M | 1 |
| Dohi, O; Hara, T; Inada, Y; Inoue, K; Itoh, Y; Iwai, N; Kagawa, K; Komaki, T; Konishi, H; Naito, Y; Oka, K; Okuda, T; Tsuji, T | 1 |
| Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Tani, S; Umemura, K; Uotani, T; Yamade, M | 1 |
| Adachi, K; Ebi, M; Funaki, Y; Hijikata, Y; Izawa, S; Kasugai, K; Ogasawara, N; Sasaki, M; Shinmura, T; Yamaguchi, Y | 1 |
| Asahina, A; Kikuchi, S; Nobeyama, Y; Saeki, H | 1 |
| Hayashi, Y; Kobayashi, Y; Lefor, AK; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Tani, S; Umemura, K; Yamade, M | 1 |
| Fujioka, Y; Hashiguchi, K; Imamura, I; Kakiuchi, T; Kawakubo, H; Matsuo, M; Mizoe, A; Nakayama, A; Okuda, M; Yamaguchi, D; Yamamoto, K | 1 |
| Ando, T; Handa, O; Horie, R; Imamoto, E; Itoh, Y; Murakami, T; Ose, T; Sendo, R; Suzuki, N | 1 |
| Gotoda, T; Horii, T; Ichijima, R; Ikehara, H; Kusano, C; Suzuki, S | 1 |
| Graham, DY; Lu, H; Shiotani, A | 1 |
| Akiyama, J; Cho, H; Hisada, Y; Iwata, E; Kawazoe, M; Kimura, K; Kobayakawa, M; Komori, S; Mishima, S; Nagata, N; Okahara, K; Okubo, H; Shimada, T; Shimomura, A; Shiroma, S; Takasaki, Y; Uemura, N; Watanabe, K; Yanagisawa, N; Yokoi, C | 1 |
| Graham, DY; Howden, CW | 1 |
| Eto, H; Gotoda, T; Ichijima, R; Ikehara, H; Ito, H; Kawabe, K; Kawamura, M; Kusano, C; Nakahara, M; Suzuki, S; Yoda, Y | 1 |
| Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
| Deguchi, H; Fukuhara, S; Kamitani, T; Yamamoto, Y; Yamazaki, H | 1 |
| Borody, TJ; Clancy, A; Dawson, MVM; Gunaratne, AW; Hamblin, H; Magat, AJMC; Tu, J | 1 |
| Chan, FKL; Lui, RN | 1 |
| Bunchorntavakul, C; Buranathawornsom, A | 1 |
| An, H; He, Y; Huang, T; Jiang, Z; Li, S; Lin, H; Yang, C; Yuan, J | 1 |
| Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S | 1 |
| He, C; Hu, Y; Li, NS; Lu, NH; Ouyang, YB; Peng, C; Shu, X; Xie, C; Xie, Y; Xu, X; Zhu, Y; Zhu, ZH | 3 |
| Ang, D; Ang, TL; Chan, YH; Koo, SH; Krishnasamy-Balasubramanian, JK; Kumar, R; Kwek, AB; Li, JW; Lin, KW; Ong, PJ; R, R; Soon, GH; Tan, CK; Tan, TY; Tan, Y; Tan, YJ; Wong, YJ | 1 |
| Chey, WD; Howden, CW; Hunt, BJ; Laine, L; López, LJ; Mégraud, F | 1 |
| Hu, Y; Lu, NH; Ouyang, Y; Wang, M; Xu, YL; Zhu, Y | 1 |
| Fallone, CA | 1 |
| Cheng, H; Gao, W; Li, Y; Teng, G; Wang, C; Xu, Y | 1 |
| Hu, Y; Lu, NH | 1 |
| Ang, D | 1 |
| Hu, W; Sun, Y; Yue, L | 1 |
| Endo, H; Esaki, M; Fujimoto, K; Fujioka, Y; Fukuda, K; Hanada, K; Hashiguchi, K; Imamura, I; Kajiwara, T; Kakiuchi, T; Kawakubo, H; Matsunaga, K; Matsunaga, T; Matsuo, M; Muro, E; Noda, T; Ogata, S; Sakata, Y; Sumino, M; Watanabe, A; Yamaguchi, D; Yamamoto, K; Yoshimura, M | 1 |
| Adachi, K; Ebi, M; Funaki, Y; Izawa, S; Kasugai, K; Kato, S; Koshino, A; Nagao, K; Ogasawara, N; Ohashi, W; Sasaki, M; Sugiyama, T; Yamaguchi, Y; Yoshimine, T | 1 |
| Gotoda, T; Ishibashi, F; Suzuki, S | 1 |
| Cheng, H; Dong, J; Dong, X; Gao, W; Ge, C; Liu, B; Liu, J; Teng, G; Wang, X; Xu, Y; Ye, H; Zhang, X | 1 |
| Liu, L; Nahata, MC | 1 |
| Love, BL; Yunusa, I | 1 |
| Dang, YN; Gao, X; Li, LR; Li, WJ; Li, X; Qian, HS; Xu, XB; Yang, Z; Yuan, L; Zhang, GX; Zhang, M; Zhang, WF | 1 |
| Ishibashi, F; Mochida, K; Morishita, T; Nagai, M; Suzuki, S | 1 |
| Graham, DY | 1 |
| Ding, YM; Duan, M; Han, ZX; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Mu, YJ; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL | 1 |
| Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL | 1 |
| Kajihara, Y | 1 |
| Düzenli, T; Kaya, M; Köseoğlu, H; Sezikli, M | 1 |
| Huang, J; Lin, Y | 1 |
| Chen, HW; Liu, JJ; Lu, Y; Peng, X; Su, PZ; Wan, Y; Yao, JY; Yu, J; Zhang, M; Zhi, M | 1 |
| Feuerstein, JD; Flynn, DJ | 1 |
| Fan, LL; Guo, Y; He, P; Hu, J; Lan, CH; Liu, YX; Mei, H; Pan, J; Su, NY; Sun, WJ; Wang, XW; Zhang, DK; Zou, PY | 1 |
| Chan, P; Cheung, K; Deng, Z; Han, S; Li, K; Li, Y; Luo, X; Lyu, T; Ni, L | 1 |
| Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y | 1 |
| Du, RC; Hu, Y; Lu, NH; Ouyang, YB | 1 |
| Guo, Y; Hu, J; Lan, CH; Liu, HN; Liu, HQ; Liu, YX; Mei, H; Shi, Q; Su, NY; Wang, XW | 1 |
| Eiamsitrakoon, T; Graham, DY; Mahachai, V; Ratana-Amornpin, S; Sanglutong, L; Siramolpiwat, S | 1 |
| Chen, J; Chen, Y; Ding, XW; Han, YY; Hu, YL; Li, PY; Li, SL; Lin, Y; Liu, F; Long, H; Su, CX; Wang, QY; Xu, M; Zhang, ZY; Zhou, L | 1 |
| Dai, X; Qin, L; Yang, F; Yu, B | 1 |
15 review(s) available for clarithromycin and vonoprazan
| Article | Year |
|---|---|
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance | 2017 |
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Remission Induction; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2017 |
Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.
Topics: Anti-Bacterial Agents; Clarithromycin; Clinical Protocols; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; Sulfonamides | 2018 |
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
Topics: Amoxicillin; Antimicrobial Stewardship; Clarithromycin; Drug Resistance, Bacterial; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Failure; Treatment Outcome | 2021 |
Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2022 |
Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
Optimizing
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
25 trial(s) available for clarithromycin and vonoprazan
| Article | Year |
|---|---|
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Healthy Volunteers; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.
Topics: Adult; Area Under Curve; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Half-Life; Humans; Male; Pyrroles; Sulfonamides | 2017 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Single-Blind Method; Sulfonamides; Treatment Outcome | 2017 |
Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2018 |
Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Topics: Aged; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Drug Therapy, Combination; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Probiotics; Pyrroles; Sulfonamides | 2020 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neoplasm Recurrence, Local; Pyrroles; Sulfonamides | 2022 |
Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter; Helicobacter Infections; Helicobacter pylori; Humans; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; United States | 2022 |
Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Fatty Acids, Volatile; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; RNA, Ribosomal, 16S; Sulfonamides | 2022 |
Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbiota; Proton Pump Inhibitors; Pyrroles; RNA, Ribosomal, 16S; Sulfonamides | 2022 |
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2023 |
Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2023 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Thailand | 2023 |
Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Sulfonamides; Treatment Outcome | 2023 |
44 other study(ies) available for clarithromycin and vonoprazan
| Article | Year |
|---|---|
Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Feasibility Studies; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2016 |
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; RNA, Ribosomal, 23S; Sulfonamides; Treatment Outcome; Urea | 2016 |
A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Remission Induction; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2016 |
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides | 2017 |
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Male; Metronidazole; Middle Aged; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Urea | 2017 |
Comparative study: Vonoprazan and proton pump inhibitors in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Patient Safety; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2017 |
The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Young Adult | 2017 |
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2018 |
Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
Topics: Aged; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Smoking; Sulfonamides; Treatment Failure | 2019 |
Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2019 |
A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Packaging; Drug Therapy, Combination; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atherosclerosis; Cholesterol, HDL; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lipid Metabolism; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2019 |
Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sex Factors; Stevens-Johnson Syndrome; Sulfonamides | 2020 |
Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicobacter pylori; Humans; Japan; Pyrroles; Sulfonamides | 2020 |
Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Students; Sulfonamides; Treatment Outcome | 2020 |
Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Body Size; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Interrupted Time Series Analysis; Japan; Pharmaceutical Preparations; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Australia; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Vonoprazan-containing therapy has an
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
The Current Role of Vonoprazan in Helicobacter pylori Treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in Ch
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Potassium; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Urease | 2022 |
Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; East Asian People; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2023 |
A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Metronidazole; Penicillins; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Proton Pump Inhibitors | 2023 |
A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Feasibility Studies; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Penicillins; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2023 |
Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rifabutin; Treatment Outcome; United States | 2023 |
Risk factors for adverse events in first-line Helicobacter pylori eradication therapy with vonoprazan, amoxicillin, and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Risk Factors; Treatment Outcome | 2023 |
Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
In
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2023 |